片頭痛予防におけるアトゲパントの役割: 体系的なレビューとメタ解析
Naresh Kumar Ladhwani1, Priya Bai2, Rohan Lal3
1Dow University of Health Sciences, Karachi, Pakistan.
BMC neurology
|September 2, 2025
まとめ
アトゲパントは,毎月の片頭痛と頭痛の日数を減らすことで,片頭痛を効果的に予防します. しかし,便秘や吐き気などの胃腸の副作用のリスクが増加する可能性があります.
科学分野:
- 神経学
- 薬理学について
背景:
- アトゲパントは,カルシトニン遺伝子関連ペプチド (CGRP) 受容体抗体です.
- 片頭痛の予防治療に用いられる.
研究 の 目的:
- 片頭痛管理におけるアトゲパントの安全性と有効性を評価する.
- アトゲパントの毎月の片頭痛日,頭痛日,急性薬剤使用に対する影響を評価する.
主な方法:
- 2025年3月24日までのPubMed,Scopus,Web of Science,Cochrane CENTRALの体系的な文献検索を行いました.
- 4052人の参加者を含む6つのランダム化対照試験 (RCT) を含めた.
- 評価されたアウトカムには,MMD,頭痛の日,急性薬剤使用,TEAE,生活質スコア (MSQ,AIM-D) が含まれています. アトゲパントの投与量によるサブグループ分析が行われました.
主要な成果:
- アトゲパントは,12週間にわたって,すべての評価された用量 (10 mg, 30 mg, 60 mg) で,毎月の片頭痛 (MMD) の signicant減少を示した.
- この薬は毎月の頭痛日数と 急性薬の必要性を減らせました
- 治療による有害事象 (TEAE) が増加し,主に便秘や吐き気などの胃腸 (GI) の副作用でした. 他の副作用はほとんどなかった.
結論:
- アトゲパントは,片頭痛の予防に有効なCGRP抗薬である.
- アトゲパントの使用に関する主な懸念は,消化器官の副作用の発生率の増加である.
- 効果と安全性を調べるためにさらなる研究が必要である.
関連する概念動画
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
01:27Open Angle Glaucoma: Treatment
557
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
557
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
635
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
635
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
595
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
595